Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

NCT02670824 | Completed Phase 1 DMC

• 1 other identifier: CN-105-01
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single escalating dose and repeated doses of CN-105 in healthy adult participants. There will be about 48 subjects, 36 active and 12 placebo.

Conditions

Intracerebral Hemorrhage (ICH)

Outcome Measures

Primary Outcomes (1)

• The number and percentage of participants having study procedure-related suspected adverse reactions assessed by change from baseline in vital signs, ECG and clinical labs.

  The number and percentage of participants having study procedure-related suspected adverse reactions assessed by change from baseline in vital signs, ECG and clinical labs will be tabulated and evaluated

  up to 1 week

Study Arms (2)

CN-105 Active Drug

EXPERIMENTAL

The CN-105 drug administered via IV at an escalating scale of mg/kg. A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg

Drug: CN-105

Placebo

PLACEBO COMPARATOR

Normal Saline

Drug: Placebo

Interventions

CN-105 DRUG

Single and multiple intravenous (IV) doses of CN-105

CN-105 Active Drug

Placebo DRUG

Normal Saline

Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Capable of giving written Informed Consent to participate in the study prior to undergoing any screening procedures.
• Non-smoking and does not use nicotine-containing products (including smoking cessation aids, such as gums or patches) for 6 months or greater at study commencement
• Adult male or female volunteers between 18 and 50 years (inclusive) at screening
• BMI between 18-33 kg/m2 (inclusive) and weighing at least 110 lbs (50 kg).
• Healthy on the basis of the medical history, physical examination, vital signs, ECG, blood chemistry, hematology, and urinalysis performed at screening.
• Adequate peripheral forearm vein access.
• No significant dietary restrictions and willing to fully consume all Duke CRU "Regular Diet" meals and beverages/water provided to them.
• Women who are of non-childbearing potential, must be:
• Surgically sterile (removal of both ovaries and/ or uterus at least 12 months prior to dosing).
• Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dosing on Day -1 and with an FSH level at screening of ≥ 40 mIU/mL.
• Women of child-bearing potential must have a negative serum pregnancy test at screening and urine pregnancy test during the study, and must agree to avoid pregnancy during study and for three months after the last dose of study drug. Pregnancy is tested at screening, during check-in, during the follow-up visit, and at any given point if deemed necessary to the PI or designate. During treatment, women of child-bearing potential must use two acceptable methods of contraception at the same time unless the subject has had a documented tubal sterilization or chooses to use a Copper T 380A IUD or LNG 20 IUS, in which case no additional contraception is required. Medically acceptable contraceptives include: (1) documented surgical sterilization (such as a hysterectomy), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) hormonal contraception (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring) or (4) an intrauterine device (IUD) or intrauterine system (IUS). Abstinence is not an acceptable form of contraception in this study.
• Male participants must agree to take all necessary measures to avoid causing pregnancy in their sexual partners during the study and for three months after the last dose of study drug. Medically acceptable contraceptives include: (1) surgical sterilization (such as a vasectomy), or (2) a condom used with a spermicidal. Contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use.
• Must not have donated blood, platelets, or any other blood components 30 days, or plasma 90 days, prior to consenting. Must also agree not to donate blood, platelets, or any other blood components for 3 months after the last dose of study drug.
• Male participants must agree not to donate sperm during the study and for 12 weeks after the last dose.
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

You may not qualify if:

• Laboratory results outside the normal range, if considered clinically significant (CS) by the PI or delegate. Any laboratory result outside the normal range and not clinically significant will be designated as such by NCS (Non-clinically Significant).
• Mental capacity that is limited to the extent that the participant cannot provide legal consent or understand information regarding the side effects of the study drug.
• Currently abusing drugs or alcohol or with a history of drug or alcohol abuse within the past two years or drinks more than 3 cups of coffee per day.
• Unwillingness or lack of ability to comply with the protocol, or to cooperate fully with the PI and site personnel.
• Clinically significant ECG abnormality in the opinion of the PI or delegate.
• Has taken any other investigational drug during the 30 days or 5 half-lives (whichever is longer) prior to the screening visit or is currently participating in another investigational drug clinical trial.
• History or manifestation of clinically significant neurological (e.g., frequent headaches or migraines), gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematologic or other medical disorders that might influence the interpretation of the results of the study.
• Infected with Hepatitis B or C or HIV Virus.
• Participants who have a history of unexplained syncope or fainting from the collection of blood; i.e., autonomic dysfunction.
• Lack of ability to understand verbal and/ or written English
• Subjects who had significant trauma or surgical procedure within 1 month prior to Screening.
• A positive urine drug screen or positive alcohol breathalyzer test.

Sponsors & Collaborators

• AegisCN LLC: lead

Study Sites (1)

Duke Clinical Research Institute

Durham, North Carolina, 27705, United States

Location

Related Publications (1)

• Li S, Wangqin R, Meng X, Li H, Wang Y, Wang H, Laskowitz D, Chen X, Wang Y. Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants. Clin Ther. 2022 May;44(5):744-754. doi: 10.1016/j.clinthera.2022.03.006. Epub 2022 May 11.

  PMID: 35562205 DERIVED

MeSH Terms

Conditions

Cerebral Hemorrhage

Interventions

apolipoprotein E mimetic peptide CN-105

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2016
• First Posted: February 2, 2016
• Study Start: December 1, 2015
• Primary Completion: May 1, 2016
• Study Completion: August 1, 2016
• Last Updated: August 18, 2016

Record last verified: 2016-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)